文献速递心律失常

肺静脉隔离后继续与停用抗心律失常药物对复发性房颤的影响:POWDER AF多中心随机试验

PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial.
PubMed 文献 · Eur Heart J · 2018-01-01

POWDER AF多中心随机试验纳入接受接触力指导肺静脉隔离的阵发性房颤患者,在3个月空白期继续使用既往无效抗心律失常药物,空白期结束时无房颤者按1:1随机继续用药(ADT ON组77例)或停药(ADT OFF组76例),随访至术后1年。主要终点(任何记录到的持续>30秒房性快速性心律失常)在ADT ON组2/74(2.7%) vs ADT OFF组16/73(21.9%),P<0.001,继续用药显著减少术后1年复发。

要点

  • 空白期后继续既往无效ADT显著降低PVI术后1年房性快速性心律失常复发(2.7% vs 21.9%,P<0.001)。
  • ADT ON组重复消融率(1.4% vs 19.2%,HR=0.053,95%CI 0.007-0.399,P<0.01)和计划外心律失常相关就诊率(2.7% vs 20.5%,HR=0.055,95%CI 0.007-0.410,P<0.01)均更低。
  • 两组生活质量评分相似。

核心结论

  • 在3个月空白期结束时无房颤的患者中,继续使用既往无效的抗心律失常药物可显著减少PVI术后第1年房性快速性心律失常复发。

研究设计与样本

  • 多中心、随机对照研究,纳入接受接触力指导肺静脉隔离的阵发性房颤患者,空白期3个月内继续既往无效ADT;空白期结束无房颤者按1:1随机分为ADT ON组(n=77)和ADT OFF组(n=76),随访至PVI后1年,采用改良意向性治疗原则分析主要终点。

主要发现

  • 主要终点(任何记录到的持续>30秒房性快速性心律失常)在ADT ON组2/74(2.7%) vs ADT OFF组16/73(21.9%),P<0.001。
  • ADT ON组重复消融率1.4% vs 19.2%(HR=0.053,95%CI 0.007-0.399,P<0.01)。
  • ADT ON组计划外心律失常相关就诊率2.7% vs 20.5%(HR=0.055,95%CI 0.007-0.410,P<0.01)。
  • 两组生活质量评分相似。
  • 每组各有3例失访。

临床怎么用

  • 对于PVI术后3个月空白期结束时无房颤的阵发性房颤患者,可考虑继续使用既往无效的抗心律失常药物以降低术后1年复发风险。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Catheter ablation is indicated in patients with symptomatic paroxysmal atrial fibrillation (AF) resistant to antiarrhythmic drug therapy (ADT). We investigated whether continued use of previously ineffective ADT beyond the post-ablation blanking period reduces recurrence of atrial tachyarrhythmia within the 1st year after ablation. METHODS AND RESULTS: This was a multicentre, randomized controlled study in patients undergoing contact force-guided pulmonary vein isolation (PVI) for paroxysmal AF in whom previously ineffective ADT was continued during a blanking period of 3 months. If free of AF at the end of the blanking period, patients were randomly assigned in the ratio of 1:1 to continue ADT (ADT ON group, n = 77) or discontinue ADT (ADT OFF group, n = 76). Patients were followed up until 1 year after PVI, with clinical visits, Holter monitoring, and quality-of-life (QOL) questionnaires at 6 and 12 months post-procedure. Analysis of the primary endpoint (any documented atrial tachyarrhythmia lasting >30 s) was performed according to the modified intention-to-treat principle. Secondary endpoints included repeat ablation, unscheduled visits, and QOL score. Baseline clinical characteristics and initial ablation procedure characteristics were comparable between both groups. Three patients were lost to follow-up in each arm. The primary endpoint was observed in 2 of 74 (2.7%) patients in the ADT ON group vs. 16 of 73 (21.9%) patients in the ADT OFF group (P < 0.001). The ADT ON group had a lower rate of repeat ablation [1.4% vs. 19.2%, hazard ratio (HR) = 0.053; 95% confidence interval (CI) 0.007-0.399; P < 0.01) and less unscheduled arrhythmia-related health care visits (2.7% vs. 20.5%, HR = 0.055, 95% CI 0.007-0.410; P < 0.01). Quality-of-life scores were similar in both groups. CONCLUSION: In patients free of AF at the end of 3 months of post-ablation blanking period, continued use of previously ineffective ADT significantly reduces the recurrence of atrial tachyarrhythmia in the 1st year after PVI.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Duytschaever M, Demolder A, Phlips T, et al. PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. Eur Heart J. 2018. PMID: 29211857. doi:10.1093/eurheartj/ehx666

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。